Novartis - Articles and news items

Relocating the EMA: An open letter from EFPIA and Pharma Heads of Research

Industry news / 16 May 2017 / European Federation of Pharmaceutical Industries and Associations (EFPIA)

The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines

Novartis enter agreement with Conatus for NASH treatment

Industry news / 10 May 2017 / Niamh Marriott, Junior Editor

This follows the initiation of the Phase IIb trial by Conatus evaluating emricasan in patients with decompensated liver cirrhosis caused by NASH…

FDA approves new combination treatment for acute myeloid leukaemia

Industry news / 4 May 2017 / Niamh Marriott, Junior Editor

The drug is approved for use in combination with LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML…

Novartis real-world data confirms benefit of Gilenya in relapsing MS

Industry news / 28 April 2017 / Niamh Marriott, Junior Editor

Novartis announced data from the MS-MRIUS study, which confirmed the effectiveness of Gilenya (fingolimod) in the real-world setting…

migraine

Novartis to globally co-commercialise Amgen’s migraine drug

Industry news / 27 April 2017 / Niamh Marriott, Junior Editor

Novartis has expanded their commercialisation agreement with Amgen for AMG 334 (erenumab), which is being investigated for the prevention of migraine…

NIH study shows Novartis drug eltrombopag improves responses in severe aplastic anemia

Industry news / 20 April 2017 / Niamh Marriott, Junior Editor

Novartis demonstrated that 58% of patients with treatment-naïve severe aplastic anemia (SAA) achieved complete response at six months when treated…

Novartis expands development programs for NASH with Allergan clinical partnership

Industry news / 20 April 2017 / Niamh Marriott, Junior Editor

Novartis has entered into a clinical trial agreement with Allergan to conduct a Phase IIb study, involving the combination of a Novartis’ FXR agonist…

Novartis’ lymphoma treatment receives FDA breakthrough therapy designation

Industry news / 19 April 2017 / Niamh Marriott, Junior Editor

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis’ CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL), who have failed two or more prior therapies. This is the second indication for which […]

2017 Pipelines: Drugs to watch

Blog, Z Homepage promo / 12 April 2017 / Alexandra Kibble, Senior Editor, Clarivate Analytics Cortellis

The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of >$900 billion by 2021…

Novartis’ lung cancer drug combination receives EU approval

Industry news / 5 April 2017 / Niamh Marriott, Junior Editor

The European Commission has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat fnon-small cell lung cancer…

skin

Novartis’ Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause

Industry news / 15 March 2017 / Niamh Marriott, Junior Editor

Moderate-to-severe psoriasis patients treated with Cosentyx (secukinumab) rapidly regain clear skin following relapse during a treatment pause…

Sandoz biosimilar adalimumab study shows equivalent efficacy

Industry news / 14 March 2017 / Niamh Marriott, Junior Editor

Sandoz, a Novartis division, presented data for its proposed biosimilar adalimumab, GP2017, showing that their Phase III study met its primary endpoint…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+